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1084 The Journal of Thoracic and CardBackground: Indications for extracorporeal membrane oxygenation therapy have
expanded to include cardiopulmonary arrest and support after congenital heart
surgery. Data from a national registry have reported that cardiac patients have the
poorest survival of all extracorporeal membrane oxygenation recipients. Concerns
have been raised about the appropriateness of such an aggressive strategy, especially
in light of the high costs and potential for long-term neurologic disability. We
reviewed our experience with salvage cardiac extracorporeal membrane oxygen-
ation to determine the cost-utility, which accounts for both costs and quality of life.
Methods: Medical records of patients with congenital heart disease receiving sal-
vage cardiac extracorporeal membrane oxygenation between January 2000 and May
2004 were reviewed. Charges for all medical care after the institution of extracor-
poreal membrane oxygenation were determined and converted to costs by published
standards. The quality-of-life status of survivors was determined with the Health
Utilities Index Mark II.
Results: Salvage cardiac extracorporeal membrane oxygenation was instituted in 32
patients (18 for cardiopulmonary arrest and 14 for cardiac failure after heart surgery)
at a median age of 2.0 months (range, 4 days to 5.1 years). Congenital heart disease
was present in 27 (84%). The mean duration of extracorporeal membrane oxygen-
ation support was 5.1 4.1 days. Survival to hospital discharge was 50%, including
1 patient bridged to heart transplantation. Survival to 1 year was 47%. The mean
score of the Health Utilities Index for the survivors was 0.75  0.19 (range,
0.41-1.0). The median cost for hospital stay after the institution of extracorporeal
membrane oxygenation was $156,324 per patient. The calculated cost-utility for
salvage extracorporeal membrane oxygenation in this population was $24,386 per
quality-adjusted life-year saved, which would be considered within the range of
accepted cost-efficacy ($50,000 per quality-adjusted life-year saved).
Conclusions: Salvage cardiac extracorporeal membrane oxygenation results in rea-
sonable survival and is justified on a cost-utility basis.
Originally introduced for the management of respiratory distress syndromemore than 25 years ago, extracorporeal membrane oxygenation (ECMO) isnow used routinely in congenital heart disease centers.1,2 Several institu-
tions have reported that ECMO is a useful adjunct in the management of patients
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with cardiomyopathy, arrhythmia, and postoperative ven-
tricular failure.1,3,4 Despite promising results from some
centers, cardiac ECMO in children still has the poorest
survival of any ECMO indication.5 The multi-institutional
Extracorporeal Life Support Organization registry data re-
ported that the hospital survival for cardiac ECMO is 42%.6
In addition, many of the patients with congenital heart
disease have cardiac lesions that may require several pal-
liative operations and are not expected to have a normal life
expectancy. Moreover, patients with congenital heart dis-
ease are at risk for later neurologic deficits, which are likely
exacerbated by the need for ECMO in early childhood—
especially when instituted in the setting of acute cardiac
arrest.7,8 Because of these concerns and the recognition that
ECMO is an expensive resource, some have questioned the
use of ECMO for salvage therapy of children with heart
disease.
Several studies have examined the cost-effectiveness of
ECMO in other pediatric populations.9,10 Studies in North
America and Europe have suggested that ECMO is cost-
effective when it is used for the management of neonatal
respiratory failure.9-11 It is not known, however, whether
salvage cardiac ECMO is cost-effective. In this study, we
reviewed our institution’s recent experience with salvage
cardiac ECMO to report outcomes and determine cost-
utility.
Methods
Decision Analysis
With the approval of the Institutional Review Board of Emory
University School of Medicine, we constructed a decision-analytic
model to examine the cost utility of salvage cardiac ECMO. We
adopted the perspective of a clinician who must decide whether to
institute a program of routine salvage cardiac ECMO. For the
purposes of this study, salvage cardiac ECMO was defined as
institution of ECMO in the setting of (1) acute cardiac arrest for
children with underlying heart disease or (2) hemodynamic failure
after surgery for congenital heart disease. This study excluded
patients with structurally normal hearts in whom myocarditis,
arrhythmia, or both, develop and who are placed on ECMO elec-
tively. The main reason for excluding these subjects is that it is
difficult to know how they might have done had they not received
ECMO. For other pediatric conditions, such as acute respiratory
distress syndrome, investigators have developed algorithms for
risk of death, such as the Pediatric Index of Mortality. To our
knowledge, these algorithms have not been validated in the setting
of isolated cardiac disease. In the absence of such data, we be-
lieved it more appropriate to exclude children placed on ECMO
electively. Our center does not routinely use ECMO after certain
congenital heart procedures, such as the Norwood operation, as has
been advocated by some institutions.12 We included all patients
who received salvage cardiac ECMO from January 1, 2000, to
May 1, 2004. The primary outcome was cost-utility, which calcu-
lates the cost per quality-adjusted life-year (QALY) saved. Costs
                                                       are reported in 2003 US dollars.
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Medical costs. Costs of hospitalization from the time of insti-
tution of ECMO to hospital discharge were obtained from direct
hospital charges. Hospital charges included all chargeable items,
nonphysician personnel time, and physician charges. Hospital
charges were converted to costs based on the cost-charge ratio
(0.5604) for Children’s Healthcare of Atlanta.13
Future medical costs. The analysis accounted for medical
costs that would be incurred after hospital discharge for survivors.
For patients with a single ventricle, the mean costs of a bidirec-
tional Glenn procedure (Current Procedural Terminology 33767)
and a modified Fontan procedure (Current Procedural Terminol-
ogy code 33619) were derived from hospital sources. The cost of
additional prosthetic mitral valve operation was not included,
because the timing for such operations can vary considerably
among patients. We assumed an annual visit with a cardiologist
and a limited echocardiographic examination and electrocardio-
gram on a semiannual basis for all subjects with congenital heart
disease. Costs for these encounters were derived from published
Medicare sources.14,15 Annual costs for lifetime medications, such
as digoxin, angiotensin-converting inhibitors, diuretics, or immu-
nosuppressants, for those undergoing heart transplantation were
included in the model. We did not include costs for noncardiology
medical services or medications.
Cost-utility analysis. Utility data—to evaluate the quality of
life—in children and adults with congenital heart disease are
lacking. However, to make comparisons between salvage cardiac
ECMO and other public health interventions, we used the Health
Utilities Index Mark II (HUI-2).15 The HUI-2 is a 15-item ques-
tionnaire designed to ask the minimum number of questions re-
quired to classify a subject’s health status. Parents completed the
HUI-2 in all cases. From questionnaire responses, one can derive
a multiattribute utility function. Scores range from death to full
health (0 to 1.00). The HUI-2 has been shown to have reasonable
interrater reliability and has previously been applied to a number
of other pediatric disease states.16,17
Life expectancy. Because the study was limited to patients
receiving salvage cardiac ECMO, we assumed that mortality
would be 100% had the subjects not been placed on ECMO.
Subsequent costs and life-years saved were, therefore, calculated
from the time of institution of ECMO onward. Although historical
studies have demonstrated that the survival for patients with con-
genital heart disease is less than for the healthy population, out-
comes have been improving in recent decades. Therefore, for
patients with 2-ventricle circulation, life expectancy was assumed
to be normal: 77.2 years, according to recent vital statistics.18 The
life expectancy for children with single-ventricle heart lesions was
assumed to be 40 years. The median life expectancy of 40 years in
single-ventricle patients was derived from an expected 10-year
survival of 80% and a 10% risk of death per decade on the basis
of analysis of historical cohorts.19
Discount rate. All future costs and benefits were discounted at
a rate of 3%. Discounting is used to calculate life-years lost.
Sensitivity Analysis
For cost-utility analysis, we evaluated the sensitivity of the model
to variations in key assumptions over various ranges. We varied
the hospital mortality for salvage cardiac ECMO in congenital
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score0.20 to a maximum of 1.0 to account for the possibility that
health status might change significantly in later years.
Results
Between January 1, 2000, and May 1, 2004, cardiac ECMO
was instituted in 39 patients. Seven subjects with normal
cardiac anatomy and myocarditis, arrhythmias, or both were
placed on ECMO electively and had a hospital survival of
86%. Salvage cardiac ECMO was used in 32 patients (18 for
cardiopulmonary arrest, 11 for failure to wean from bypass
after surgery, and 3 for ventricular dysfunction, pulmonary
hypertension, or both immediately after surgery) at a me-
dian age of 2.0 months (range, 4 days to 5.1 years; Table 1).
Congenital heart disease was present in 27 (84%). Among
the congenital heart defects were hypoplastic left heart
syndrome (n  6), other single-ventricle disease (n  5),
total anomalous pulmonary venous connection (n  3),
interrupted aortic arch (n  2), anomalous left coronary
from the pulmonary artery (n  2), double-outlet right
ventricle (n 2), mitral stenosis (n 2), tetralogy of Fallot
(n  2), pulmonary atresia with ventricular septal defect
(n  1), D-transposition of the great arteries (n  1), and
heart transplantation (n  1). One subject had VATER
syndrome,* and 1 patient had DiGeorge syndrome. Three
patients were placed on ECMO for cardiac arrest at presen-
tation and underwent congenital heart operation later during
that hospitalization.
The mean duration of ECMO support was 5.1  4.1
days. Survival to hospital discharge was 50%, including
1 patient who was bridged to heart transplantation. Sur-
vival to 1 year for the entire cohort was 47%. Two of the
initial 16 hospital survivors subsequently died. One death
occurred 5 months after ECMO decannulation in a patient
with low cardiac output after a Glenn procedure for
TABLE 1. Patient population
Variable No. (%)
Congenital heart disease 27 (84%)
2-ventricle anatomy 15 (56%)
1-ventricle anatomy 12 (44%)
Prior cardiac surgery 26 (81%)
Prior cardiac surgery, same admission 22 (69%)
Indication for ECMO
Cardiopulmonary arrest 18 (56%)
Failure to separate from CPB 11 (34%)
Postoperative low cardiac output 2 (6%)
Postoperative pulmonary hypertension 1 (3%)
ECMO, Extracorporeal membrane oxygenation; CPB, cardiopulmonary
bypass.*VATER  vertebral defects, imperforate anus, tracheoesophageal fistula, and
radial and renal dysplasia.
1086 The Journal of Thoracic and Cardiovascular Surgery ● Mahypoplastic left heart syndrome. A second patient with
VATER syndrome and multiple congenital anomalies
and tracheostomy died out of hospital from acute respi-
ratory failure 21 months after discharge from ECMO
hospitalization.
Sixteen patients did not survive to hospital discharge.
Most of these deaths (n  10) occurred while subjects were
still receiving ECMO support or within 72 hours of decan-
nulation. An additional 6 subjects died more than 72 hours
after decannulation during the same hospital stay. The most
common cause of death was multiple organ system failure
(n  6). Two patients had neurologic injuries that prompted
withdrawal of ECMO support. Additional causes of death in
these subjects included cardiopulmonary arrest (n  3),
acute graft rejection after transplantation (n  1), ventric-
ular dysfunction (n  1), sepsis (n  1), pneumatosis
intestinalis (n  1), and complications with the ECMO
circuit (n  1).
While receiving ECMO support, patients were evaluated
for neurologic injury. Evaluations included neurologic ex-
aminations and brain imaging in most cases. There were 7
patients with significant neurologic events. Neuroimaging
studies demonstrated watershed infarct (n  4), embolic
infarct (n 2), small subdural hematoma (n 1), and grade
IV interventricular hemorrhage (n  1). Of the 16 subjects
who survived to hospital discharge, 3 were noted to have
gross motor weakness. Two subjects had significant cogni-
tive impairment.
Hospital Costs
For the entire cohort, the cost of hospitalization after insti-
tution of salvage cardiac ECMO for the entire cohort was
$6,530,141 (Table 2). The median hospital cost of salvage
cardiac ECMO per patient was $156,324. There was signif-
icant variation in cost even among the hospital survivors.
TABLE 2. Hospital cost for salvage cardiac ECMO
Variable
Entire cohort
(n  32)
Per hospital
survivor
Hospital costs on ECMO $4,440,496
Hospital costs decannulation
to discharge
$2,089,645
Total hospital costs after
institution of ECMO
$6,530,141 $408,133
Annual medical costs for
survivors ($/y)
$448
Cost of additional surgical
admissions
$25,680
Cost per life-year saved $19,565
Cost per QALY saved $24,386
ECMO, Extracorporeal membrane oxygenation; QALY, quality-adjusted
life-year.Hospital costs ranged from $81,413 to $1,238,004. The
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$6,901.
Calculated Follow-up Costs
Most survivors (82%) had congenital heart defects that were
likely to require lifelong care by a cardiologist. For survi-
vors with congenital heart disease, the calculated annual
mean cost of medications, evaluation by a cardiologist, and
imaging was $446 per year. Patients with single-ventricle
anatomy routinely undergo a bidirectional Glenn procedure
and modified Fontan procedure at 4 to 6 months and 18 to
24 months of age, respectively. At our institution, the mean
cost of the Glenn procedure is $24,554  $5,945, and the
mean cost of a Fontan procedure is $28,808  $7,906. The
costs of follow-up after transplantation were derived from
published literature.20 These data were included in the eco-
nomic analysis.
Health Utilities Analysis
The mean score of HUI-2 for the survivors was 0.75 0.19
(range, 0.41-1.0). There were 2 patients with severe impair-
ment and disability (utility 0.5). Three survivors reported
full health (utility of 1.0). The distribution of utility scores
is shown in Figure 1.
Cost-Utility Analysis
The median costs for hospital stay—for survivors and non-
survivors—after institution of ECMO were $156,324. The
calculated cost-utility for salvage ECMO in this population
was $24,386 per QALY saved. Sensitivity analysis is shown
in Figure 2. Using the utility scores reported by the parents,
but varying the in-hospital mortality for salvage cardiac
ECMO between 30% and 70%, resulted in a range of
cost-utility ratios from $14,255 to $32,721 per QALY
Figure 1. Distribution of utility scores from Health Utilities Index
Mark II, with mean and SD.saved. Assuming a hospital mortality of 50% but varying
The Journal of Thoracicthe utility scores by 0.20 up to a maximum of 1.0 resulted
in a range in calculated cost utility from $20,687 to $32,220
per QALY saved. Assuming the least favorable scenario—
hospital mortality of 70% and reported health utility 0.20
less than that reported by parents—produced a cost-utility
of $49,686 per QALY saved.
Discussion
This study demonstrates that the use of cardiac ECMO for
salvage therapy falls within the bounds of routinely ac-
cepted cost-utility. Even if one assumes that measures of
quality of life may be lower as patients approach adulthood
and that hospital mortality may be higher than the recent
experience at our institution, the use of salvage cardiac
ECMO still has a favorable cost-utility.
Since ECMO’s introduction in the late 1970s, outcomes
for children receiving ECMO have improved dramatically.
The hospital survival after ECMO for noncardiac condi-
tions—such as meconium aspiration syndrome, persistent
pulmonary hypertension of the neonate, and congenital di-
aphragmatic hernia—have been reported to be 93%, 83%,
and 59%, respectively.21 The outcome for children requir-
ing cardiac ECMO has been reported to be worse. The
hospital survival for children receiving any form of cardiac
ECMO is reported to be 42%, though some single-center
reports have ranged from 39% to 64%.3,22-24 Some institu-
tions have suggested that certain groups, such as those with
ventricular failure after cardiopulmonary bypass, may be at
higher risk for mortality.24 Conversely, a recent large single-
center report indicated that indications for cardiac ECMO
and underlying congenital heart defects were not associated
Figure 2. Sensitivity analysis of cost utility for salvage cardiac
extracorporeal membrane oxygenation varying both hospital mor-
tality (between 30% and 70%) and reported utility scores (0.2).
QALY, Quality-adjusted life-year.with survival.22 At our institution, patients with myocarditis
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hospital survival of 86%, whereas those receiving salvage
cardiac ECMO had a hospital survival of 50%.
Data regarding the quality of life and neurodevelopmen-
tal outcome for children who have required ECMO therapy
have been reported in recent years. Most studies have fo-
cused on patients with neonatal respiratory distress from
persistent fetal circulation or diaphragmatic hernia. In gen-
eral, these studies have reported mild to moderate develop-
mental delay. The collaborative UK ECMO trial found that
severe developmental disabilities were present in only 1 of
63 survivors.25 Functional loss was present in 19%, and
impairment without functional loss was present in 13%.
Nield and colleagues26 assessed functional status in pre-
school survivors of neonatal ECMO and found that 17%
were abnormal and 24% were “at risk.” Major neurologic
sequelae were present in 15% of survivors. D’Agostino and
colleagues27 reported that at 1 year of age, the mean mental
developmental index of the Bayley Scales of Infant Devel-
opment was 87 and that the psychomotor index was bor-
derline, at 75. Conversely, some studies have suggested that
the long-term neurologic risks for patients receiving neona-
tal ECMO are quite low. Lamers and colleagues28 reported
normal developmental outcome (a mean mental develop-
mental index of 102 and psychomotor index of 97) in 76
survivors of venoarterial ECMO for respiratory failure.
There are limited data on functional status or neuro-
developmental outcome for survivors of cardiac ECMO.
Ibrahim and colleagues7 reported that moderate to severe
neurologic impairment was present in more than 50% of
pediatric cardiac ECMO survivors. These authors postu-
lated that much of the neurologic impairment may have
been due to underlying congenital disease and the need for
circulatory arrest rather than the ECMO per se. Similarly,
Hamrick and colleagues8 reported that 50% of survivors of
cardiac ECMO had abnormal cognitive outcome, although
motor abnormalities were less common (30% of patients).
Although the present study did not include formal neurode-
velopmental testing, the HUI scores suggested significant
impairment in some survivors. The 3 subjects with the
lowest utility scores—all less than 0.6—had significant
neurologic impairment. Two of these patients had evidence
of significant ischemic neurologic injury on brain imaging,
whereas the third had congenital neurologic abnormalities.
It is interesting to note that ischemic neurologic injury can
be documented after cardiac surgery in a significant number
of neonates with congenital heart disease who do not require
ECMO support.29 Therefore, it would seem that a variety of
factors—such as congenital abnormalities, the need for
open-heart surgery with cardiopulmonary bypass, coagula-
tion, and embolic complications from the ECMO circuit—
seem to put the cardiac ECMO patients at risk for later
1088 The Journal of Thoracic and Cardiovascular Surgery ● Madevelopmental impairment, which ultimately affects quality
of life.
There are numerous studies regarding the costs and cost-
efficacy of ECMO in pediatric patients with noncardiac
lesions. Vats and colleagues9 reported that the mean hospi-
tal charges for pediatric ECMO for acute respiratory failure
were $199,096 in 1993, or the equivalent of $252,594 in
2003. The National Institutes of Health Workshop on the
Diffusion of ECMO Technology reported a cost of
$107,000 (1993 dollars) per survivor versus $122,000 per
death.30 When one adjusts for inflation, the cost of hospi-
talization for patients receiving salvage cardiac ECMO is in
the range of that reported for noncardiac patients. Studies
that have undertaken cost-effectiveness or cost-utility anal-
ysis for ECMO in noncardiac patients have generally re-
ported that ECMO is cost-effective. Vats and colleagues9
calculated that noncardiac ECMO results in a cost of $4190
per life-year saved (1994 dollars), which would be well
within the bounds of accepted cost-utility.
Although the hospital costs for salvage cardiac ECMO
seem to be similar to those for noncardiac indications of
neonatal ECMO, the calculated cost-utility is slightly less
favorable. Salvage cardiac ECMO may be somewhat less
cost-effective than noncardiac ECMO for a variety of rea-
sons. Most importantly, the hospital survival is less for
cardiac patients, which results in a considerable expenditure
for patients who do not survive. In addition, life expectancy
for children with complex congenital heart lesions, such as
a single ventricle, is less than for children with respiratory
distress in the neonatal period. Although the latter group can
reasonably be expected to have a normal life span if they
survive initial hospitalization, children with congenital heart
disease, particularly those with a complicated neonatal
course, are likely to be at risk for ventricular failure and
arrhythmias. In addition, ECMO has been proposed as a
bridge to cardiac transplantation.31,32 After transplantation,
the median time to graft failure in children is only 11.2
years, according to data from the United Organ Sharing
Network.33 Together, these factors limit the number of
life-years gained from a successful ECMO resuscitation.
Finally, disabilities limit the quality of life of survivors and
need to be considered in a cost-utility analysis. Although
disabilities do occur after noncardiac ECMO, they may be
more common after cardiac ECMO.
It is important to note that this study suggests that sal-
vage cardiac ECMO would be likely to remain cost-effec-
tive even if the hospital survival were less than that reported
in this relatively small series of patients. If one were to
assume a hospital survival of 40%—closer to the data from
national studies—salvage cardiac ECMO would remain jus-
tifiable on a cost-utility basis. Even if one decreases the
utility scores by 0.2 utilities per child—assuming that par-
ents might overrate their child’s functional status or that the
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a later age—salvage cardiac ECMO remains cost-effective.
The use of cardiac ECMO primarily as a bridge to heart
transplantation, however, may exceed the limits of routinely
accepted cost-efficacy. Previous studies have suggested that
heart transplantation in adults has a cost-utility ratio of
$25,000 and $44,300 per year of life saved.34,35 If one
included the additional costs of salvage ECMO support, it is
possible that this strategy of ECMO as a bridge to trans-
plantation might exceed the generally accepted bound of
cost-effectiveness. Our study had only a single patient
bridged to transplantation. As such, a more detailed analysis
of this unique patient population is warranted.
A number of limitations to this study design must be
recognized. Cost analysis was performed at a single insti-
tution, and the sample size was relatively small. Practice
patterns and resource use may vary significantly among
centers within the United States and cannot be extrapolated
to other countries. In addition, the study was limited to
children receiving salvage cardiac ECMO. The study did
not include children with normal cardiac anatomy and mar-
ginal hemodynamics who were placed on ECMO electively,
nor did it address the practice of routine postoperative
ECMO for certain high-risk neonatal operations such as the
Norwood procedure. Whether a similar cost utility exists for
cardiac ECMO in these settings is not known. Finally,
although the overall survival for cardiac ECMO does not
seem to have changed significantly in the last decade ac-
cording to data from the registry data, it is possible that
there will be an improved survival in cardiac ECMO par-
alleling the marked improvement seen in neonatal congen-
ital heart surgery in recent years. Some authors have sug-
gested that institution of a resuscitation cardiac ECMO
program that can be mobilized in minutes might improve
survival and reduce morbidity.3
In conclusion, the data from our study suggest that car-
diac ECMO—even when used in the setting of salvage
therapy—still falls within the bounds of routinely accepted
cost-utility.
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